HC Wainwright & Co. Maintains Buy on Autolus Therapeutics, Raises Price Target to $10

HC Wainwright & Co. analyst Emily Bodnar maintains Autolus Therapeutics (NASDAQ:AUTL) with a Buy and raises the price target from $9 to $10.